Bymetric
UK company intelligence
Company Active PRIVATE-LIMITED-GUARANT-NSC-LIMITED-EXEMPTION

Company profile

Cell and Gene Therapy Catapult

UK company 10016023, incorporated on 19 February 2016.

Advancing cell and gene therapies through powerful collaborations - Cell and Gene Therapy

Cell and Gene Therapy Catapult is a UK company with status Active founded in 2016 based in London.

Company number
10016023
Incorporated
19 Feb 2016
Companies House status
Active

Company identity

Founded / incorporated
19 February 2016

Company number 10016023

Verify at Companies House
Legal name
CELL AND GENE THERAPY CATAPULT
Company type
PRI/LBG/NSC (Private, Limited by guarantee, no share capital, use of 'Limited' exemption)
Region
London
Registered address
12TH FLOOR TOWER WING GUY'S HOSPITAL
GREAT MAZE POND
LONDON
UNITED KINGDOM
SE1 9RT
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

1 level 1 ultimate controller
1
Company Active PRIVATE-LIMITED-GUARANT-NSC-LIMITED-EXEMPTION
Cell and Gene Therapy Catapult
CRN 10016023
2
Direct and ultimate controller Active PRIVATE-LIMITED-GUARANT-NSC
Cell Therapy Catapult Limited
CRN 07964711

Latest accounts

Financial period: 1 Mar 2024 to 28 Feb 2025

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
Unknown

Company events

Reference milestones and recent Companies House filing stream events.

5 events
17 Feb
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Nov
2026

Accounts due

Accounts Due

Next accounts due date

03 Feb
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

28 Feb
2025

Accounts filed

Accounts

Last accounts made up date

19 Feb
2016

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2017
Funded years
2017, 2018, 2021
Age at first award
1 years

Projects

2021 Collaborative R&D Lead participant

ATTC Coordination

1 Apr 2021 to 31 Mar 2022

Awarded
£302,929
Total cost £302,929
2021 Centres

Patent-reported outcomes assessment to support accelerated access to advanced cell and gene therapies: PROmics

1 Apr 2021 to 31 Mar 2022

Awarded
£13,887
Total cost £13,887
2018 Centres Lead participant

ISCF Funding for Advanced Therapy Manufacturing Apprenticeships

1 Jul 2018 to 30 Apr 2021

Awarded
£1,499,198
Total cost £1,499,198

Awaiting Public Project Summary

2018 Centres Lead participant

ATTC Coordination

1 Jun 2018 to 31 Mar 2022

Awarded
£1,706,975
Total cost £1,706,975

Awaiting Public Project Summary

2017 Centres Lead participant

ISCF Funding for Phase 2 of the C&GT Catapult Manufacturing Centre

1 Aug 2017 to 31 Oct 2019

Awarded
£10,000,000
Total cost £10,000,000

Awaiting Public Project Summary

Product types

Centres Collaborative R&D